<?xml version="1.0" encoding="UTF-8"?>
<p id="Par3">SARS-CoV-2 is a highly pathogenic virus that causes COVID-19 and is overwhelming the health systems of well-resourced developed countries. According to the 
 <ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/map.html" xmlns:xlink="http://www.w3.org/1999/xlink">Johns Hopkins Coronavirus Resource Center</ext-link>, as of the 27
 <sup>th</sup> of March 2020, in Italy alone 80,589 patients had been diagnosed with COVID-19, and 8,215 fatalities had occurred. Doctors in Italy have been forced to face excruciating decisions about which patients should receive access to limited resources such as mechanical ventilation
 <sup>
  <xref ref-type="bibr" rid="CR2">2</xref>
 </sup>. The severe nature of the SARS-CoV-2 infection also exacerbates resource limitations, as patients often need 15–20 days of ventilation
 <sup>
  <xref ref-type="bibr" rid="CR2">2</xref>
 </sup>. Many patients are severely or critically ill, and fatality rates have been higher than for viruses such as influenza
 <sup>
  <xref ref-type="bibr" rid="CR3">3</xref>
 </sup>. Within this context, rheumatologists are understandably worried that COVID-19 could pose a considerable risk to their patients.
</p>
